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ABSTRACT
Neurodegeneration refers to a heterogeneous group of
brain disorders that progressively evolve. It has been
increasingly appreciated that many neurodegenerative
conditions overlap at multiple levels and therefore
traditional clinicopathological correlation approaches to
better classify a disease have met with limited success.
Neuronal network disintegration is fundamental to
neurodegeneration, and concepts based around such a
concept may better explain the overlap between their
clinical and pathological phenotypes. In this Review,
promoters of overlap in neurodegeneration incorporating
behavioural, cognitive, metabolic, motor, and
extrapyramidal presentations will be critically appraised.
In addition, evidence that may support the existence of
large-scale networks that might be contributing to
phenotypic differentiation will be considered across a
neurodegenerative spectrum. Disintegration of neuronal
networks through different pathological processes, such
as prion-like spread, may provide a better paradigm of
disease and thereby facilitate the identiﬁcation of novel
therapies for neurodegeneration.
INTRODUCTION
Considerable debate exists regarding neurodegen-
eration, an umbrella term that incorporates a wide
range of neurological disorders with heterogeneous
clinical and pathological expressions affecting dis-
tinct subsets of neurons in speciﬁc functional ana-
tomic systems showing a relentless progression.1
Traditionally, the study of neurodegenerative disor-
ders has relied on a conventional clinicopathologi-
cal approach, deﬁning a particular clinical
diagnoses (such as Alzheimer’s disease), and
attempting to match this to a pattern of pathology
in the brain. However, it is increasingly recognised
that there is considerable clinical and pathological
overlap across neurodegenerative disorders
(ﬁgure 1). Patients with frontotemporal dementia
(FTD) may present with amyotrophic lateral scler-
osis (ALS) and vice versa;2 patients with parkiniso-
nian plus syndromes (including corticobasal
degeneration (CBD) and progressive supranuclear
palsy (PSP) phenotypes) may present with initial
cognitive changes,3 while patients with FTD may
develop prominent extrapyramidal symptoms
resembling parkinsonian plus syndromes.4
Pathologically, there appears to be limited correl-
ation linking speciﬁc syndromes such that both tau
and Tar-DNA binding protein (TDP)-43 pathology
can result in behavioural variant FTD (bvFTD),2
while corticobasal syndrome (CBS) may be asso-
ciated with both CBD and Alzheimer’s disease
pathology.5 As such, current clinicopathological
approaches fail to recognise the heterogeneity of
these conditions.
An alternative approach to the classiﬁcation of
neurodegenerative disorders invokes neural net-
works, deﬁned as a series of interconnected neural
nodes that determine physiological function.6 7
These networks occur at microscopic (neurons and
synapses), macroscopic or structural (anatomical
regions and ﬁbres), and functional (physiological
connections) levels.6 There is a wealth of literature
describing speciﬁc networks based on functional
and structural imaging modalities.8 More recently,
the concept of pathological networks based on
pathogenic proteins, known as ‘molecular nexopa-
thies’,6 has been developed. It has been suggested
that the susceptibility and phenotype will vary con-
tingent on the involvement of speciﬁc neural net-
works.7 In this Review the overlap between
neurological conditions in terms of clinical pheno-
type (behaviour, cognitive, primary motor, extra-
pyramidal, and metabolic) rather than syndromic
diagnoses will be discussed, and the evidence sug-
gesting widespread network involvement in neuro-
degeneration will be critically appraised. Network
involvement in neurodegenerative language disor-
ders will not be discussed, but extensive reviews are
available.9 Evidence for network dysfunction at a
genetic and pathological level, and how neurode-
generation may spread along these networks in a
prion-like manner will be discussed in addition to
transgenic mouse models that may play a role in
mapping network involvement across neurodegen-
erative disorders.
Clinical phenotypes and neurodegenration
Behavioural phenotypes in neurodegeneration
Behavioural changes have been associated with a
range of clinicopathological diagnoses, but are most
characteristic of bvFTD, as reﬂected in current
diagnostic criteria. Patients with bvFTD typically
present with changes in behaviour ranging from
apathy – with reduced motivation, inertia, and a
lack of interest in previous hobbies – to disinhib-
ition manifesting in impulsive and often socially
inappropriate actions such as overspending, gam-
bling, or sexually inappropriate remarks. Mental
rigidity and stereotypical behaviour is also widely
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reported by caregivers, leading to alterations in food preferences
and eating behaviour. Similar, prominent behavioural symptoms
have been recorded in other neurodegenerative disorders,
including ALS and a number of parkinsonian plus syndromes
that display signiﬁcant overlap with FTD.2 Patients with ALS
may develop prominent behavioural features including apathy,
loss of empathy, emotional lability, and less commonly gluttony,
behavioural stereotypes and compulsions. Patients with ALS
may occasionally develop neuropsychiatric and behavioural
symptoms prior to the onset of classic motor symptoms.10 In a
number of parkinsonian plus syndromes, such as PSP and CBS,
there is increasing evidence for prominent behavioural change,
including apathy,11 12 impaired social engagement,12 and
impaired emotional expression.13 It has recently been suggested
that behavioural changes may be present in up to 30% of
patients with PSP.3 Patients with CBS and the language variants
of FTD (semantic dementia) also develop difﬁculties with
behaviour and emotion processing.14 Given the clinical overlap
seen in behaviour and emotion processing in these disorders, it
is likely that commonalities exist in the disruption or dysfunc-
tion of networks controlling these phenotypic behaviours.
Neural networks and behaviour
The last decade has witnessed a surge of evidence proposing
dysfunction within large-scale neural networks; these relate to
resting state and intrinsic connectivity functional MRI (fMRI),
EEG and MEG studies that correlate with clinical presentations
of abnormal behaviours in neurodegenerative diseases. Three
major networks have been associated with aberrant behaviours
in neurodegenerative diseases—the salience network (SN), the
default mode network (DMN) and the executive-control
network (ECN).
The SN is centred on the dorsal anterior cingulate cortex
(dACC) and frontoinsular cortex with extensive links to both
cortical and subcortical regions, including the superior temporal
pole, the dorsolateral prefrontal cortex, the amygdala, thalamus,
hypothalamus, and the substantia nigra/ventral tegmental area.15
In terms of behaviour, the SN is implicated in detecting, analys-
ing, and integrating emotionally salient stimuli with respect to
the internal environment.15 Within the network, the anterior
insula is involved in salience detection, whereas the anterior cin-
gulate functions as a modulator of behaviour. The anterior
insula, together with the extended SN and input from the pos-
terior insula, integrates internal sensory stimuli to produce a
socially appropriate behavior, for example, wearing appropriate
clothing for the season. Not only is the insula activated during
internal sensory stimuli, it also shows activation to external
emotionally salient stimuli such as love, compassion, empathy,
disgust, anger, and happiness.16
While the SN is critical for self-awareness, self-control and
emotion regulation, it also has a modulatory effect on the
DMN – another large-scale network involved in behaviour and
cognition (including autobiographical memory, prospection, and
theory of mind) and intrinsically linked to the ECN.17 The
DMN comprises a network of brain regions with core regions
in the posterior cingulate cortex (PCC), lateral parietal cortex
and medial prefrontal cortex (mPFC), and prominent connec-
tions to nodes in the medial temporal lobe (MTL) and angular
gyrus. The DMN is reciprocally deactivated during attention-
demanding tasks which activate the SN. In contrast, a number
of speciﬁc non-stimulus driven cognitive functions activate the
DMN; autobiographical memory, and episodic memory are
associated with activation of nodes in the PCC, while theory of
mind and moral reasoning are associated with activation of spe-
ciﬁc nodes in the mPFC.18 19 The reciprocity of DMN and SN
activation in moral reasoning exempliﬁes the role of the anterior
insula in modulating behaviour by switching between large-scale
networks.20 As mentioned, the DMN is activated in healthy par-
ticipants during moral reasoning tasks; however, during these
tasks there is also directed functional connectivity to nodes
within the SN. This functional connectivity between the DMN
and SN is diminished when patients with FTD show poor moral
reasoning.21 Finally, the ECN links the dorsolateral frontal and
parietal neocortices as well as the dorsal caudate and anterior
insula, and is primarily involved in manipulating and maintain-
ing information in working memory, sustained attention,
response selection to goal-directed behavior, and inhibition.15 22
Depending on the task, the ECN and the DMN show antagonis-
tic responses. For example, when a participant is involved in an
attention-demanding task in which self-referential and episodic
memory is unnecessary, then the ECN is engaged and the DMN
is disengaged,23 network changes that are facilitated by the SN
and in particular, the anterior insula.
Common neural networks for the behavioural phenotype in
neurodegeneration
As mentioned previously, many abnormal behaviours (including
apathy and poor social interactions) are pervasive among an
array of neurodegenerative conditions (including ALS, FTD,
PSP, CBD and AD). Although these conditions show a variety of
clinical phenotypes with distinctive neuroanatomical, neuroima-
ging, and genetic signatures, their shared behavioural deﬁcits
could be explained in terms of network disruption.
Mounting evidence exists for involvement of the SN in FTD,
particularly in relation to bvFTD.24 These ﬁndings converge
with results from structural imaging studies which demonstrate
atrophy of key regions of the SN, including the anterior cingu-
late cortex, insula and subcortical structures (including the
amygdala, striatum and thalamus), all regions which have been
implicated in complex social and emotional processing.25
Furthermore, reduced SN connectivity correlates with disease
severity.26 27 Considering the role of the SN and in particular,
the anterior cingulate in terms of behaviour modulation, it is
not surprising that patients with abnormalities in this network,
and particularly patients with FTD, show profound disinhibited
behaviour with loss of social graces and reduced empathy. In
Figure 1 Clinical and pathological overlap in neurodegeneration:
showing overlap at both a phenotypic and pathological level between
multiple neurodegenerative conditions.
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contrast, studies of DMN connectivity in FTD have shown con-
ﬂicting results that perhaps can be reconciled in light of the
top-down inﬂuence of the SN on the DMN, as discussed
above.8 Theory of mind deﬁcits are intrinsically linked to auto-
biographical memory and prospection through connectivity in
the mPFC of the DMN in healthy participants.28 Deﬁcits in
‘theory of mind (ToM)’ are often profound in FTD; these
patients are unable to imagine the thoughts and experiences of
others, and are often unsympathetic to issues which do not
concern themselves and these, in turn, can cause conﬂict within
personal relationships.29 30 Deﬁcits in ToM have also been iden-
tiﬁed in patients with ALS and PSP, thus supporting the hypoth-
esis that these conditions merge in terms of abnormalities in the
DMN.31 32 In AD, the DMN consistently shows reduced con-
nectivity, and this again corresponds to atrophy patterns in AD
and has been shown to predict disease severity and progres-
sion.33 34 Similarly, the relative preservation or intensiﬁcation of
SN activation is in parallel with the preservation of manners
and social decorum until late in AD, but has been shown to be
associated with aberrant motor behaviour, anxiety, and
irritability.35
In comparison, patients with ALS have shown inconsistent
results in terms of network connectivity.24 36 37 A number of
theories arise in terms of resolving the conﬂict between studies.
The ﬁrst enhanced connectivity may occur in ALS due to loss of
cortical inhibition, and is in keeping with ﬁndings from one
study that found a greater rate of disease progression in those
with the most functional connectivity;38 39 the second that
enhanced functional recruitment may occur in one region to
compensate for loss of function in another, a compensatory
mechanism that is early and may be lost as the network disinte-
grates and cognitive deﬁcits increase.40 Finally, the heterogeneity
of the ALS phenotype, particularly in terms of cognitive and
behavioural features, may inﬂuence and be inﬂuenced by the
pattern of network degeneration.
Further insights may be gained by exploring the complex
interactions within and between large-scale neural networks in
PSP and CBS, which show overlapping behavioural abnormal-
ities and structural changes with FTD. The network degener-
ation theory has been conﬁrmed in CBS,41 but as yet no
published data exists regarding the nature of intrinsic connectiv-
ity abnormalities in these disorders in relation to behavioural
changes.
Cognitive phenotype in neurodegeneration
Episodic memory dysfunction represents a hallmark feature of
AD with patients typically experiencing difﬁculties in the encod-
ing and retrieval of recently experienced events. Irrespective of
the domain of testing, patients with AD display signiﬁcant
impairments on standard neuropsychological tests of visual and
verbal recall, as well as gross impairments in the retrieval of per-
sonally relevant autobiographical memories from their past and
adaptive forms of memory such as prospective memory. The
MTL represent one of the earliest sites of pathology in AD,
leading to the common assumption that episodic memory
impairment reﬂects MTL dysfunction.42 It is evident, however,
that regions beyond the MTL, such as the PCC/retrosplenial
cortex, also play a crucial role in the origin of memory dysfunc-
tion in AD.43 It has been argued that disruption of functional
connectivity between the hippocampus and posterior parietal
regions represents a key modulator of episodic memory disrup-
tion in AD.44
While memory dysfunction is regarded as a phenotypic
feature of AD, mounting evidence points to signiﬁcant episodic
memory disturbance in other neurodegenerative disorders, thus
suggesting that the diagnostic utility of traditional neuropsycho-
logical memory tasks may be more limited. For example, a
severe amnestic presentation remains an exclusion criterion for
the diagnosis of bvFTD; yet a number of studies converge to
reveal striking memory impairments equivalent to that of
matched cases of AD.18 These deﬁcits occur irrespective of the
domain of testing of the standardised tests for verbal and visual,
immediate and delayed, recall, autobiographical memory45 and
prospective memory.46 Further impairments are evident for
source memory, with bvFTD cases unable to correctly retrieve
the spatial or temporal context of previously presented items.47
Given that the locus of atrophy in FTD typically affects fron-
toinsular cortices, it was initially assumed that episodic memory
difﬁculties in bvFTD reﬂected prefrontal cortical degeneration.
Recent studies unequivocally point to the involvement of MTL,
notably the hippocampus, in driving episodic memory deﬁcits
in bvFTD.43 48 Accordingly, it is clear that signiﬁcant overlap
exists in the neural circuitry mediating episodic memory deﬁcits
in bvFTD and AD, with the hippocampus representing a critical
nexus in this system.
Common neural networks for the cognitive phenotype in
neurodegneration
The advent of sophisticated neuroimaging techniques has served
to clarify the complexity of the neural circuitry which supports
episodic memory in humans, conﬁrming that engagement of a
distributed network of cortical regions exhibiting strong connec-
tions with the MTL is essential for episodic memory retrieval.49
Key cortical regions in this network include frontal regions such
as the medial prefrontal cortex as well as posterior parietal
structures, including the retrosplenial/PCC and the angular
gyrus.50 The hippocampus appears particularly well placed to
support episodic memory retrieval given its dense projections
with prefrontal51 and midline posterior cortical structures.44 In
addition, subcortical structures, such as the thalamus and fornix,
are becoming increasingly recognised for their role in support-
ing episodic retrieval, further underscoring the complexity of
this system. Damage to any node of this large-scale network or
alterations in the functional connectivity therein will result in
compromised memory performance, as evident in the
large-scale network dysfunction observed in the dementias.18
Primary motor/extrapyramidal phenotype and cognition in
neurodegeneration
The archetypical overlap syndrome between loss of primary
motor function and cognition is that of FTD and ALS.
Symptoms of cognitive dysfunction and FTD can occur in ALS,
and patients with FTD can develop limb weakness and bulbar
dysfunction. There is also increasing awareness of an overlap in
clinical phenotyping between extrapyramidal symptoms, includ-
ing parkinsonism, bradykinesia, rigidity and gait abnormalities,
and cognitive changes within the parkinsonian plus syndromes;
in other words, it is often difﬁcult to separate a diagnoses of
FTD (behavioural and language variants) from CBS and PSP.
Patients can often present with any of these movement disorders
and go on to develop cognitive symptoms, most commonly in
the form of behavioural change. Presentation may be with cog-
nitive deﬁcits and also involve other domains,4 including
aphasia, apraxia of speech,52 limb apraxia, and visuoconstruc-
tive deﬁcits.4 Further complicating the issue is that patients with
different genetic causes of FTD, including the C9orf72 expan-
sion, microtubule associated protein tau (MAPT) and progranu-
lin (GRN) mutations, can develop features of parkinsonism,
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with both MAPT and progranulin mutations in particular being
associated with CBS and PSP.
Common neural networks for the primary motor/extrapyramidal
phenotype in neurodegneration
Structural and functional imaging studies have indicated that
networks involved in the primary motor deﬁcits of ALS func-
tionally and anatomically involve regions associated with the
motor cortices.53 On diffusion tensor imaging the corpus callo-
sum has been found to be consistently affected in ALS; the
hypothesis is that it is integral for the pathological spread in the
brain.54 Voxel-based morphometry shows atrophy of motor cor-
tices occurs in the primary motor phenotypes of both FTD and
ALS, with additional atrophy also found in the left middle and
inferior frontal gyri, the anterior portion of the superior frontal
gyri, the superior temporal gyri, the temporal poles and the left
posterior thalamus, and the non-motor regions known to be
involved in pure bvFTD.55 56 This broader pattern of atrophy
potentially explains the spectrum of motor and cognitive
changes seen across FTD and ALS.
The extrapyramidal symptoms associated with parkinsonian
plus syndromes differ depending on the clinical syndrome.
Atrophy in PSP is localised to the midbrain, pons, thalamus and
striatum; in CBS, bilateral atrophy of the premotor cortex,
superior parietal lobules, and striatum occurs.57 It has been sug-
gested that PSP participants with an extrapyramidal syndrome
have more brainstem atrophy and less cortical atrophy than CBS
participants.58 Studies examining network connections in PSP,
using white matter tract diffusion tensor imaging and functional
MRI, found disruption of network connectivity between the
cerebellum, midbrain, thalamus, and premotor cortex.59 It has
been suggested that PSP is associated with disrupted thalamocor-
tical connectivity and the dentatorubrothalamic tract.60 An alter-
native study has suggested involvement of a network anchored
by the dorsal midbrain and with connections including the
brainstem, basal ganglia, diencephalic, cerebellar and cortical
regions.61 A network such as this could potentially explain the
mixed motor, behavioural and cognitive features observed in
PSP. Further studies have suggested that white matter track
degeneration differs between PSP, Parkinson’s disease, multisys-
tems atrophy, and CBS.62 63 Studies of overlap in networks
responsible for the extrapyramidal symptoms in PSP, CBD and
FTD have been limited, but such network overlap is likely given
the strong clinical overlap between these conditions. Further
research involving structural and functional imaging across these
disorders would prove to be fruitful.
Metabolic phenotype in neurodegeneration
Recently it has been suggested that the overlap in neurodegen-
erative diseases may extend beyond motor and cognitive fea-
tures, and involve more systemic bodily functions such as
metabolism. Insulin resistance and type 2 diabetes appear to
play an important role in modulating neurodegenerative dis-
eases; an increased incidence of peripheral insulin resistance and
diabetes is identiﬁed in a number of neurodegenerative condi-
tions, including AD, Parkinson’s disease, Huntington’s disease
ALS and FTD.64–68 How insulin promotes neurodegeneration
remains unclear, but it may exert a peripheral and central inﬂu-
ence. Proposed mechanisms include the promotion of oxidative
stress, inﬂammation, vascular dysfunction, and impairment of
neurogenesis and neuronal repair.69 Typically, insulin resistance
and metabolic changes have been viewed as consequences of
obesity. Mounting evidence indicates, however, that several neu-
rodegenerative conditions – including AD, Huntington’s disease
and ALS – are associated with signiﬁcant weight loss, often
prior to diagnosis,70 implying that these metabolic changes may
be part of the neurodegenerative process rather than a conse-
quence of obesity. Further, metabolic change may underlie
phenotypic changes in behavior, such as in bvFTD, where
patients develop prominent changes in eating behaviour with
hyperphagia and changes in food preference.71 This could have
a subsequent effect on insulin and cholesterol levels.
Common neural networks for the metabolic phenotype in
neurodegeneration
There is increasing evidence for networks controlling eating
behavior, and neuroendocrine control and metabolism in condi-
tions such as bvFTD,72 with involvement of reward networks,
the hypothalamus and changes in neuroendocrine peptides.72 At
a pathological and imaging level, other neurodegenerative con-
ditions show changes in the neuroendocrine system, including
ALS73 and Huntington’s disease;68 these are conditions exhibit-
ing hypothalamic atrophy. Further work is required to map the
neural networks in neurodegeneration that inﬂuence behav-
ioural change and metabolism directly.
Pathology and neurodegeneration
Does pathology correlate better to phenotypic networks than to
clinical diagnostic syndromes?
Evidence for involvement of networks in neurodegeneration at
a pathological level is growing.6 Recently, the concept of
‘molecular nexopathies’ proposes that pathological proteinopa-
thies can target speciﬁc networks, and multiple functional net-
works can be targeted by these proteinopathies. This in turn
leads to phenotypic variation and potential overlap between
these disorders.6 This model is enticing especially given the
hypothesis that proteinopathies may spread in a ‘prion’ like
manner. Prions are deﬁned as proteinaceous infectious particles
consisting of misfolded prion protein that aggregate together
and act as ‘seeds’ that result in a chain reaction causing further
misfolding and aggregation, and these spread throughout the
central nervous system. A prion hypothesis for disease spread
has been hypothesised for a number of neurodegenerative con-
ditions, including amyloid in AD,74 TDP-43 in FTD and ALS,
Tau in Pick’s disease, and PSP75 and synuclein in Parkinson’s
disease.74
In terms of the pathological networks corresponding to clin-
ical phenotypic networks (ie, behaviour, cognitive, primary
motor, extrapyramidal, and metabolic) this is an emerging area.
To date, the examination of pathological networks has been
based around the traditional clinical diagnostic syndromes (eg,
Alzheimer’s disease) rather than on the phenotypic networks
highlighted above. The most developed pathological networks
in terms of correlation to clinical phenotypic networks involve
the β-amyloid and TDP-43 proteins, with tau an emerging area
of research.
β-amyloid and the cognitive network
In AD it has been hypothesised that β-amyloid spreads in prion-
like manner giving different pathological stages of β-amyloid
deposition.74 β-amyloid ﬁrst accumulates in the basal temporal
and orbitofrontal neocortex, then spreads throughout the neo-
cortex and then to the hippocampi, amygdala, diencephalon
and basal ganglia. Then ﬁnally, in severe cases, this spreads to
the mesencephalon, lower brainstem, and cerebellar cortex.74 76
How this pathological spread interacts with clinical phenotypic
networks remains to be elucidated. There is emerging research
examining this with β amyloid being found to preferentially
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deposit in the DMN network and higher order intrinsic con-
nectivity networks, including the frontoparietal network, with
areas showing decreased functional activity including both areas
exhibiting β-amyloid deposition and atrophy.77 Frequently,
however, in AD there is a disparity between the presence of
pathology (eg, β-amyloid) and functional impairment.78 A
recent study examined the functional impairment between var-
iants of Alzheimer’s disease (early onset, logopenic variant, and
posterior cortical atrophy) as measured by 18F-labelled ﬂuoro-
deoxyglucose positron emission tomography (FDG-PET), and
β-amyloid deposition as measured by (11)C-labelled Pittsburgh
compound B.78 It was found that the AD variants had degener-
ation in speciﬁc functional networks, while their pattern of
β-amyloid deposition varied, often being diffuse.78 This suggests
that the location of β-amyloid deposition may not ﬁt the
network patterns involved in the clinical variability seen
between AD syndromes.78 Further work is required to under-
stand the interaction between clinical phenotypic networks, and
deposition of pathology along these networks and more
diffusely.
TDP-43 and the primary motor and behavioural networks
In ALS it has being suggested that spread of TDP-43 pathology
may occur in a recognised centrifugal pattern with four stages
of spread.79 TDP-43 accumulation begins in the motor neocor-
tex, progressing to the spinal cord and brainstem with involve-
ment of frontal-parietal regions, and ﬁnally to the temporal
lobes.79 Such a pattern of spread may potentially explain the
eventual development of cognitive symptoms in ALS and the
predominant clinical phenotype of motor signs. In bvFTD,
TDP-43 pathology is suggested to develop with a frontooccipital
gradient involving initial accumulation in frontal regions, then
premotor, primary motor, parietal and occipital cortices.80 This
pattern of pathological spread explains the initial prominent
behavioural changes followed by involvement of other cognitive
functions as the disease progresses.80
Tau Pathology and networks
Neuronal tau pathology networks have been described in AD
with neuronal tau inclusions developing in the locus coeruleus,
as well as in the transentorhinal and entorhinal cortices (stages I
and II). This is followed by the presence of neuronal tau inclu-
sions in the hippocampal formation and some parts of the neo-
cortex (stages III and IV), followed by large parts of the
neocortex (stages V and VI).74 How these stages relate to differ-
ing clinical phenotypic networks has not been examined, nor
has the relationship between phenotypic networks and the glial
tau pathologies of CBD and PSP.
How transmission occurs along pathological networks
There is growing evidence from animal models that transmission
may occur in a prion-like fashion along neurons connected in
networks. A recent study shows that injection of human brain
extracts from patients suffering different tauopathies (including
AD, Pick’s disease, PSP, and CBD) resulted in the formation of
tau inclusions in ALZ17 transgenic mice.81 Similar attempts
were trialled several decades ago by Gajdusek and Gibbs in pri-
mates with limited success.82 Hypotheses of how cell-to-cell
transmission occurs varies between diseases, with suggestions
that include trans-synaptic transmission, transmission through
membrane channels, and glial cell intrusions into neurons.83 84
In ALS it has been suggested that transmission between neur-
onal networks may occur via glia with which endocytose extra-
cellular protein material;83 however, the oligodendrocytes along
such connected pathways are unlikely to be involved since they
do not accumulate TDP-43 protein.85 In PSP and CBD, with
such obvious glial tau pathology, this may be a more dominant
mechanism and the tau oligomers are considered as most
responsible for the spread of pathology through the brain.86 It
is potentially possible that susceptibility of speciﬁc cells to spe-
ciﬁc proteinaceous material may vary, and this along with the
susceptibility of various functional networks may be responsible
for the heterogeneity of clinical phenotypes as well as their
overlap. Why some clinical phenotypic networks (eg, the behav-
ioural network) may be susceptible to several proteins (eg, tau
and TDP-43) while the primary motor network, as in ALS,
seems more susceptible to only TDP-43 pathology remains
elusive. It likely involves genetic, epigenetic and environmental
interactions.
Do genetic abnormalities correlate better to phenotypic
networks than to pathology and clinical diagnostic
syndromes?
Genetic mutations involved in neurodegenerative diseases
A given clinical syndrome is often associated with several differ-
ent genetic mutations and underlying pathologies. FTD is a
good example. There are a wide range of causative genes for
FTD, including C9orf72, MAPT and GRN, and other rarer
causes including VCP, CHMP2B, FUS, TARBP, DCTN1 and
SQSTM1. At a clinical level, C9orf72, MAPT and GRN are all
most commonly associated with a bvFTD clinical presentation;
however, even though they are associated with a similar clinical
picture, C9orf72 and GRN are associated with TDP-43 path-
ology, while MAPT mutations are associated with underlying tau
pathology. The clinical syndrome of pure ALS is also associated
with a common clinical presentation, but with variable under-
lying genetic mutations and pathology. ALS is associated with
mutations in SOD1, TARDBP, FUS and GGGGCC expansions in
C9orf72. At a pathological level, most cases are associated with
TDP-43 pathology;87 SOD-1 mutation cases, however, do not
have TDP-43, but have neuronal SOD1 inclusions. CBD and
PSP can be associated with MAPT mutations,88 and autosomal
dominant AD has been associated with mutations in the
Amyloid precursor Protein (APP) and presenilin 1 and 2, with
late onset risk associated with allelic variation of apolipoprotein
E. How this multitude of genetic mutations can be associated
with differing pathologies, but overlapping clinical phenotype is
not known; thus, the examination of genetic mutations in rela-
tion to network dysfunction may prove to be fruitful.
To date, despite a wealth of literature regarding the relation-
ship between genetic mutations and pathological changes, and
speciﬁc brain atrophy on imaging, there has been limited exam-
ination of the relationship between genetic mutations and either
clinical phenotypic functional or pathological networks;
however, this is an emerging area. In bvFTD, both C9orf72
mutation carriers and non-carriers showed convergent break-
down of large-scale networks despite different atrophy patterns,
with behavioural symptoms correlating with diminished SN con-
nectivity and heightened default node connectivity.89 This area
of research will be likely to provide useful insights into the net-
works underlying neurodegeneration and clinical phenotypic
heterogeneity, and will also provide useful insights into the
molecular functioning of genes within networks and hence, in
therapeutic trials. The mapping of networks in relation to
genetic mutations also offers the prospect of being able to
examine the network function of presymptomatic carriers and
identify network involvement early on in the disease process. It
has been found that GRN mutation carriers change decades
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before the onset of the disease in functional brain networks that
begin in the parietal region and then spread to the anterior
brain.90 The relationship between genes and neural networks
will also provide an important link between animal models and
these functional networks as many animal models are based on
a speciﬁc genetic mutation.
Use of mouse models to map networks
Transgenic mice, and other animal models, have been instrumen-
tal to further our understanding of neurodegenerative diseases.
While the ﬁrst models used transgene-mediated expression of
human amyloid precursor protein (APP) to model aspects of AD,
other models followed to reﬂect tauopathies by transgenic
expression of tau, ALS by expression of TDP-43, SOD1 or more
recently through transgenic expansion of C9orf72 repeats.
Neuronal network aberrations and hyperexcitability have been
described for transgenic mouse models using EEG91 and
imaging.92 Interestingly, network aberrations and hypersynchro-
nous discharges and hyperexcitability91 are detectable in APP
mice preceding notable β-amyloid deposition93, and cognitive
deﬁcits in APP transgenic mice are apparent at early stages. The
early involvement of neuronal network abnormalities before
marked pathology reﬂects ﬁndings in human functional imagin-
ing studies, and suggests that soluble APP products (eg,
β-amyloid or β-amyloid oligomers) rather than β-amyloid
plaques are involved in the generation of network impairments
and likely cognitive deﬁcits. The animal data also suggests that
network aberrations and hyperexcitability are linked. Key techni-
ques used in mouse models to analyse neuronal network function
are electroencephalography (EEG) and computational methods
to mine EEG data for network performance. Several recording
types appear particularly relevant as their network features can
be related to cognitive performance by computational means.
Hippocampal recordings from the cornu ammonis (CA) region,
for example, provide insight on performance and topology of
pyramidal/interneuronal connections that are reﬂected in EEG γ
and theta oscillations and their phase coupling.94 Spontaneous
and induced hyperexcitability has also been observed in tau trans-
genic mouse models.95 However, detailed analysis of network
topology by EEG or electrophysiology of single cells in situ in tau
transgenic mice have not been performed. Network alterations in
ALS mouse models using SOD1, TDP-43 overexpression, or
C9orf72 repeat expansion have also not been addressed. Further
research is required into how network aberrations and hyperex-
citability are linked in such disease-relevant animal models.
In addition to functionally studying networks in animal
models, the recent advances in optogenetics have now made
manipulation of neuronal systems in vivo feasible.96 Combining
functional network analysis by EEG, electrophysiology or
imaging with induced changes in activity of speciﬁc neuronal
ensembles using optogenetics could prove to be a valuable tool
to address whether network aberrations can be manipulated or
even reversed by speciﬁcally targeting subsets of neurons (eg,
interneurons). Insights from these induced network outputs can
then be correlated with cognitive performance. Mouse models,
therefore, are a past and future tool to test these basic hypoth-
eses on disease-relevant network mechanisms and to help drive
better targeted therapies.
Figure 2 Neurodegenerative network map: proposed way forward for a collaborative approach based on phenotypic variation, imaging, pathology
and genetics for investigating the neural networks and their contribution to the pathophysiological bases of neurodegenerative conditions. A better
understanding of the neural networks involved is likely to translate into better targeted treatments based on these networks. DTI, diffusion tensor
imaging; PET, positron emission tomography.
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FUTURE APPROACHES
Based on the available literature, it is proposed that the clinical
and pathological heterogeneity of neurodegenerative disorders
remains fundamentally related to the functioning of underlying
neural networks. Understanding these networks and how they
are intrinsically involved will not only advance our clinical
understanding of these conditions and their varying phenotypes,
but also provide greater insight into their pathophysiology. The
standard approach of examining one aspect of these conditions
and mapping it to a particular brain region through neuroima-
ging and pathological examination has met with limited success,
perhaps resulting in therapeutic failures. A potential way to
overcome this problem would be to take ecologically valid tasks
that show changes across multiple neurodegenerative conditions
(eg, a task measuring behavioural change) and use multiple
imaging techniques – both structural and functional – to map
the brain networks in multiple conditions (ﬁgure 2) and under-
stand their speciﬁc genetic susceptibilities. Using these networks,
pathological involvement could be examined in addition to the
potential for spread along these networks at the cellular and
molecular levels. Insights into the processes and patterns of
molecular spread of neurodegenerative conditions may also be
gained by comparing animal models with relevant susceptible
genetic mutations for the networks involved. Understanding a
neural network of neurodegeneration and patterns of disease
spread and progression via such networks seems likely to
promote new treatment approaches.
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